Plus de 40 ans d’expérience à votre service

Tel. : 01 45 33 67 17 / E-mail : coger@coger.fr

Stock épuisé.
En rupture de stock
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte

 

 

COVID-19

Latest Insights & Products for SARS-CoV-2/COVID-19 Research


Go to:

>> Coronaviruses (CoVs) - SARS-CoV & SARS-CoV-2 [2019-nCoV]

>> ACE2 & Functional Receptor for SARS Coronaviruses

>> Biological Therapeutic Strategies against SARS-CoV-2 and COVID-19

>> COVID-19 Diagnostics

>> Cytokine Storm and Severity of COVID-19

>> Overview on the AdipoGen Life Sciences Panel of Products (Biologicals)

>> Overview on the AdipoGen Life Sciences Panel of Products (Small Molecules)

 

Coronaviruses (CoVs) - SARS-CoV & SARS-CoV-2 [2019-nCoV]

Coronaviruses (CoVs) are enveloped non-segmented positive-sense RNA viruses infecting human and vertebrates. They are classified into four types (genus), α-CoV, β-CoV, γ-CoV and δ-CoV. They can infect the respiratory, gastrointestinal, hepatic and central nervous system of human and many wild animals. The family of Coronaviridae constantly circulates within the human population and mainly causes mild respiratory diseases. Recently, a new severe acute respiratory syndrome β-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome called coronavirus human disease 2019 or COVID-19. Typical clinical symptoms of these patients are dry cough, fever, breathing difficulties, headache and pneumonia. Disease onset may result in progressive respiratory failure, heart tissue damage and even death.

SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein (see Figure 1). The SARS Envelope (E) protein plays a role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.

The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor, and a large ectodomain that consists of a receptor binding S1 subunit and a membrane-fusing S2 subunit (see Figure 2, adapted from Cell, Hofmann, et al. (2020)). The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells. 

 

LITERATURE REFERENCES:

  1. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status: Y.R. Guo, et al.; Mil. Med. Res. 7, 11 (2020) (Review)
  2. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor: M. Hoffmann, et al.; Cell (Epub ahead of print) (2020)
  3. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine: W. Tai, et al.; Cell Mol. Immunol. (Epub ahead of print) (2020)
  4. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2: R. Yan, et al.; Science 367, 1444 (2020)
  5. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein: A.C. Walls, et al.; Cell (Epub ahead of print) (2020) (Review)

 

 


ACE2 & Functional Receptor for SARS Coronaviruses

Angiotensin-converting enzyme 2 (ACE2) is a type I transmembrane metallocarboxypeptidase within the renin-angiotensin system (RAS), which plays a key role in blood pressure regulation, fluid and electrolyte balance, thirst, cardiac/renal function and growth. ACE2 is expressed on the cell surface of type 2 alveolar epithelial cells in the lungs as well as on cells in many other tissues. ACE2 shares approximately 60% homology with ACE, the other key enzyme of the RAS system.  

ACE2 converts angiotensin II (Ang II) into Ang(1–7), which acts on the Mas receptor and plays a role in cardiovascular disease to lower blood pressure through vasodilation and by promoting kidney sodium and water excretion, but also to lower inflammation. The effects of ACE2 directly oppose those induced by ACE–Ang II signaling, whereby ACE converts Ang I into Ang II, which increases blood pressure by inducing vasoconstriction, increasing kidney reabsorption of sodium and water and promoting inflammation.

ACE2 has been identified as a key receptor on target cells for SARS-CoV infections in 2002. ACE2 functions as the entry receptor of the new SARS-CoV-2 coronavirus that emerged in China in 2019 and is the cause of the new disease COVID-19. Strong binding of the spike protein of SARS-CoV-2 to ACE2, along with proteolytic cleavage of ACE2 by transmembrane serine protease 2 (TMPRSS2), facilitates entry of the virus into cells, viral replication and cell-to-cell transmission. The spike protein priming by the co-receptor serine protease TMPRSS2 is crucial for SARS-CoV-2 infection of target cells and spread of the coronavirus throughout the host (see Figure 3).

 

LITERATURE REFERENCES:

  1. Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: M. Gheblawi, et al.; Circ. Res. (Epub ahead of print) (2020)
  2. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor: M. Hoffmann, et al.; Cell (Epub ahead of print) (2020)

 

 


Biological Therapeutic Strategies against SARS-CoV-2 and COVID-19

18 years ago the SARS-CoV lead to respiratory diseases in infected people. To date there are no effective vaccines against any type of the coronavirus, which can cause pneumonia and possibly bronchitis. Nevertheless, there are several strategies that are being pursued.

 

 

Soluble Human ACE2:
The novel coronavirus uses membrane-bound ACE2 as the receptor. The soluble form of ACE2 lacks the membrane anchor and circulates in small amounts in the blood. This soluble form may act as a competitive interceptor of SARS-CoV-2 and other coronaviruses by preventing binding of the viral particle to the surface-bound, full-length ACE2.

ACE2 fused to the Fc portion of immunoglobulin has been reported to neutralize SARS-CoV-2 in vitro. Soluble recombinant human ACE2 protein could actually be beneficial as a novel biological therapeutic to combat or limit infection progression caused by coronaviruses that utilize ACE2 as a receptor. 

Human ACE2 Blocking Antibodies:
Treatment with blocking anti-ACE2 antibodies disrupts the interaction between virus and receptor, neutralizing the spread of SARS-CoV-2.

Spike S (RBD) Protein:
The CoV spike (S) protein plays the most important role in viral attachment, fusion and entry and serves as a target for development of antibodies, entry inhibitors and vaccines. The soluble recombinant RBD (receptor binding domain) of coronavirus (including SARS-CoV-2) Spike proteins exhibit significantly high binding affinity to ACE2 receptor and could block the binding by competing with the virus. Attachment of recombinant SARS-CoV-2 RBD to ACE2-expressing cells could inhibit the infection to host cells.

SARS-CoV-2 Antibodies:
SARS-CoV2 specific antibodies could cross-react with SARS-CoV-2 proteins, mainly the Spike, but also the envelope, membrane and nucleocapsid proteins, and SARS-CoV-2 induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV-2 proteins-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infections. Spike (RBD) seems to be a strong immunogenic domain of coronaviruses with a large part of the antibody immune response that is directed against this region.

 

LITERATURE REFERENCES:

  1. Angiotensin‑converting enzyme 2 (ACE2) as a SARS‑CoV‑2 receptor: molecular mechanisms and potential therapeutic target: H. Zhang, et al.; Intensive Care Med. 46, 586 (2020) (Review)
  2. Therapeutic options for the 2019 novel coronavirus (2019-nCoV): G. Li & E. De Clercq; Nat. Rev. Drug Discov. 19, 149 (2020) (Review)
  3. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor: M. Hoffmann, et al.; Cell (Epub ahead of print) (2020)
  4. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2: J.M. Penninger, et al.; Cell (Preprint) (2020)
  5. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? D. Batlle, et al.; Clin. Sci. 134, 543 (2020)

 


COVID-19 Diagnostics

As the world is struggling to contain the novel coronavirus (COVID-19) outbreak, healthcare infrastructure and testing capacity have emerged as major issues. There is an urgent need for access to accurate and standardized diagnostics for SARS-CoV-2 (the causative agent of COVID-19). Laboratory testing for COVID-19 and the associated SARS-CoV-2 virus includes methods that detect the presence of the virus (PCR technology) and those that detect antibodies produced in response to infection. Detection of antibodies (serology) can be used both for clinical purposes and population surveillance. AdipoGen Life Sciences has an ongoing pipeline for detection of soluble ACE2, antibodies against SARS-CoV-2 and a HTS detection kit for the determination of SARS-CoV-2 blocking reagents. 

 

LITERATURE REFERENCES:

  1. Detection of antibodies against SARS-CoV-2 in patients with COVID-19: Z. Du, et al.; J. Med. Virol. (Epub ahead of print) (2020)

New  SARS-CoV-2 Inhibitor Screening Kit

AdipoGen Life Sciences has developed a High Throughput Screening (HTS) detection assay for the determination of SARS-CoV-2 blocking reagents.

This assay is available as as SARS-CoV-2 Inhibitor Screening Kit (Prod. No. AG-48B-0001), including all important and necessary components. 

The SARS-CoV-2 Inhibitor Screening Kit contains key reagents required to facilitate identification of SARS-CoV-2 inhibitors. This inhibitor screen is based on a colorimetric ELISA kit, which measures the binding of the RBD of the Spike S protein from SARS-CoV-2 to its human receptor ACE2. This assay allows to identify and characterize the effect of different inhibitory molecules including antibodies or chemicals on the prevention of binding of SARS-CoV-2 virus to any ACE2-expressing cells. It allows the in-house coating of the plate with either the SARS S1 protein or the ACE2 protein, allowing the customer to decide which type of inhibitors he wants to screen for. All required components for both approaches are provided and in addition an ACE2 human blocking antibody is provided as a positive control as a reference.

Figure: Binding of human ACE2 to the Spike protein of SARS-CoV-2 is inhibited by the antibody anti-ACE2 (human), mAb (blocking) (AC384) (preservative free) (AG-20A-0037PF).

 

 

 

 

 

 


Reagents for SARS-CoV-2/COVID-19 Research

Validated Recombinant Proteins for ACE2 & COVID-19 Research

 

Product Name

PID

Source

Purity

Application/Activity

ACE2 (human) (rec.)

AG-40B-0192

HEK293 cells

≥95% (SDS-PAGE)

Soluble human ACE2 competitively inhibits SARS-CoV-2 infection.

ACE2 (human) (rec.) (Biotin)

AG-40B-0192B

HEK293 cells

≥95% (SDS-PAGE)

Soluble human ACE2 competitively inhibits SARS-CoV-2 infection.

ACE2 (human):Fc (human) (rec.)

CHI-B232006

HEK293 cells

≥90% (SDS-PAGE)

Soluble human ACE2 competitively inhibits SARS-CoV-2 infection.

ACE2 (mouse) (rec.)

AG-40B-0193

HEK293 cells

≥95% (SDS-PAGE)

Soluble mouse ACE2 negative control.

SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His)

CHI-B232004

HEK 293 cells

≥90% (SDS-PAGE)

Soluble Protein S (RBD) competitively inhibits SARS-CoV-2 infection. For drug and antibody screening applications and immunization.

SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) 

CHI-B232003

HEK 293 cells

≥95% (SDS-PAGE)

Soluble Protein S (RBD) competitively inhibits SARS-CoV-2 infection. For drug and antibody screening applications and immunization.

SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.)

AG-40B-0194

HEK 293 cells

≥95% (SDS-PAGE)

Soluble Protein S (RBD) competitively inhibits SARS-CoV-2 infection. For drug and antibody screening applications and immunization.

SARS-CoV-2 Nucleocapsid Protein (rec.) (His)

CHI-B233501

E. coli

≥95% (SDS-PAGE)

For drug screening applications.

PLpro (SARS Coronavirus) (rec.) (His)

SBB-DE0024

E. coli

≥95% (SDS-PAGE)

Involved in the processing of the viral polyprotein.

ISG15 (human) (rec.) (Rhodamine 110)

SBB-PS0002

E. coli

≥97% (LCMS)

PLPro substrate. Inhibits viral budding and acts as IFNγ-inducing cytokine.


UNIQUE  Human ACE2 Monoclonal Blocking Antibody 

AdipoGen Life Sciences' anti-ACE2 (human), mAb (blocking) (AC384) (preservative free) (Prod. No. AG-20A-0037PF) is a monoclonal antibody that recognizes human ACE2 and works specifically in ELISA, Western Blot and Functional Application. The antibody blocks the binding of human ACE2 to the Spike protein of SARS-Cov-2.

Figure: Binding of ACE2 (human) to the Spike protein of SARS-CoV-2 is inhibited by the antibody anti-ACE2 (human), mAb (blocking) (AC384) (AG-20A-0037PF).


Method: SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (AG-40B-0194) is coated on an ELISA plate at 1µg/ml. ACE2 (human), mAb (blocking) (AC384) (AG-20A-0037PF) or an unrelated mAb Control are added (starting at 40µg/ml with a two-fold serial dilution) together with 500ng/µl of ACE2 (human) (AG-40B-0192). After incubation for 1h at RT, the binding was detected using an anti-FLAG antibody (HRP).

 

 


Flow Cytometry-Competent  Human ACE2 Monoclonal Antibodies 

AdipoGen Life Sciences' anti-ACE2 (human), mAb (AC18F) (Prod. No. AG-20A-0032) is a monoclonal antibody clone that recognizes human ACE2 and works specifically in Flow Cytometry (FACS). The antibody is available in different formats, unlabeled (#AG-20A-0032) and Biotin-labeled (#AG-20A-0032B), as well as labeled with the dyes ATTO488 (#AG-20A-0032TD) and ATTO647N (#AG-20A-0032TS). All variants are FACS-competent using the appropriate secondary reagents.

Figure: Detection of endogenous human ACE2 by different formats of anti-ACE2 (human), mAb (AC18F) (AG-20B-0032).


Method: HepG2 cell line is stained with anti-ACE2 (human), mAb (AC18F) (red line) or an appropriate isotype control at 1µg/106 cells each, revealed with a secondary reagent and then analyzed by flow cytometry. 

 

Download: Cell Detachment Protocol for FACS. 

 

 


All Human ACE2 Antibodies

 

Product Name

PID

Isotype

Applications

Species

anti-ACE2 (human), mAb (AC18F)

AG-20A-0032

Mouse IgG1κ

ELISA, FACS, WB

Human

anti-ACE2 (human), mAb (AC18F) (Biotin)

AG-20A-0032B

Mouse IgG1κ

ELISA, FACS, WB

Human

anti-ACE2 (human), mAb (AC18F) (ATTO 488)

AG-20A-0032TD

Mouse IgG1κ

FACS

Human

anti-ACE2 (human), mAb (AC18F) (ATTO 647N)

AG-20A-0032TS

Mouse IgG1κ

FACS

Human

anti-ACE2 (human), mAb (AC384)

AG-20A-0037

Mouse IgG1κ

ELISA, WB

Human

anti-ACE2 (human), mAb (AC384) (Biotin)

AG-20A-0037B

Mouse IgG1κ

ELISA, WB

Human

anti-ACE2 (human), mAb (blocking) (AC384) (preservative free)

AG-20A-0037PF

Mouse IgG1κ

FUNC (Blocking), ELISA, WB

Human

anti-ACE2 (human), pAb

AG-25A-0042

Rabbit

ELISA, WB

Human


New SARS-COV-2 Recombinant Antibodies in the Pipeline

 

Product Name

PID

Isotype

Applications

Species

anti-SARS-CoV-2 Spike Protein S1 (RBD), mAb (rec.) (Covi-1) (preservative-free)

AG-27B-6005PF

Human IgG1

ELISA, WB, FUNC (in validation)

SARS-CoV-2 RBD

anti-SARS-CoV-2 Spike Protein S1 (RBD), mAb (rec.) (Covi-2) (preservative-free)

AG-27B-6006PF

Human IgG1

ELISA, WB, FUNC (in validation)

SARS-CoV-2 RBD

 


Antiviral Compounds - Potential Small Molecule Therapeutics Against COVID-19

There are no approved drugs to treat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19). Existing drugs, that have a known favorable safety profile, are being examined for strategies to treat the disease and fast-track a treatment plan. Several influenza and HIV drugs are currently undergoing clinical trial in coronavirus patients. The rational selection of drugs already on the market is being made based on their ability to inhibit any proteins essential for virus-receptor interaction and/or viral life cycle.

 

LITERATURE REFERENCES:

  1. Recent discovery and development of inhibitors targeting coronaviruses: T. Pillaiyar, et al.; Drug Discov. Today (Epub ahead of print) (2020)
  2. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds: A.T. Ton, et al.; Mol. Inform. (Epub ahead of print) (2020)
  3. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines: X. Liu & X.J. Wang; J. Genet. Genomics 47, 119 (2020)
  4. Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning: P. Wang, et al.; ChemRxiv (Preprint) (2020)
  5. Structure of Mpro from COVID-19 virus and discovery of its inhibitors: Z. Jin, et al.; Nature (Epub ahead of print) (2020)

 

AdipoGen Life Sciences offers a Selection of Antiviral Small Molecules as Potential Tools for in vitro Studies of COVID-19 (not for human use).

 

Product Name

PID

CAS Number

Target

Antiviral Activity

Amastatin . hydrochloride

AG-CP3-7003

100938-10-1

Viral entry
ANPEP (Aminopeptidase N)

Viral Replication

Camostat mesylate

AG-CR1-3716

59721-29-8

Viral entry
TMPRSS2

Viral Replication

Chloroquine . diphosphate

AG-CR1-3721

50-63-5

Lysosome function
Zinc ionophore
Immunomodulation

Viral Replication

Hydroxychloroquine . sulfate

AG-CR1-3720

747-36-4

Lysosome function
Zinc ionophore
Immunomodulation

Viral Replication

Darunavir

AG-CR1-3712

206361-99-1

Papain-like viral protease (PLVP)

Viral Maturation/Replication

Darunavir . ethanolate

AG-CR1-3724

635728-49-3

Papain-like viral protease (PLVP)

Viral Maturation/Replication

Ebselen

AG-CR1-0031

60940-34-3

Main Protease (Mpro)/3C-like Protease

Viral Transcription/Replication

Elbasvir

AG-CR1-3729

1370468-36-2

RdRP, Papain-like Proteinase and Helicase

Viral Replication

Favipiravir

AG-CR1-3717

259793-96-9

RNA-dependent RNA polymerases (RdRps)

Viral Transcription/Replication

Imatinib mesylate

AG-CR1-3725

220127-57-1

Virion fusion with endosomal membrane

Viral Replication

Lopinavir

AG-CR1-3715

192725-17-0

Coronavirus endopeptidase C30 (CEP_C30)

Viral Maturation/Replication

Mycophenolic acid

AG-CN2-0419

24280-93-1

SARS-CoV-2 papain-like protease (PLpro)

Viral Replication

Nafamostat mesylate

AG-CR1-3731

82956-11-4

Viral entry
TMPRSS2

Viral Replication

Nelfinavir . mesylate

AG-CR1-3726

159989-65-8

Post-entry inhibitor

Viral Replication

Niclosamide

AG-CR1-3643

50-65-7

Endosome acidification

Viral Replication

Niclosamide . ethanolamine

AG-CR1-3644

1420-04-8

Endosome acidification

Viral Replication

Nitazoxanide

AG-CR1-3723

55981-09-4

Viral hemagglutinin
Viral IE2

Viral Maturation/
Transcription/Replication

Oseltamivir . phosphate

AG-CR1-3714

204255-11-8

Viral neuraminidase
Release of viral particles

Viral Replication

Remdesivir

AG-CR1-3713

1809249-37-3

RNA-dependent RNA polymerases (RdRps)

Viral Transcription/Replication

Remdesivir Metabolite
GS-441524

AG-CR1-3722

1191237-69-0

RNA-dependent RNA polymerases (RdRps)

Viral Transcription/Replication

Ribavirin

AG-CR1-3719

36791-04-5

RNA-dependent RNA polymerases (RdRps)
RNA capping activity
Viral mutation rates
Immunomodulation

Viral Transcription/Replication

Ritonavir

AG-CR1-3683

155213-67-5

Coronavirus endopeptidase C30 (CEP_C30)

Viral Maturation/Replication

Rosuvastatin . calcium salt

AG-CR1-3728

147098-20-2

Main Protease Mpro

Viral Replication

Ruxolitinib . phosphate salt

AG-CR1-3645

1092939-17-7

JAK1/JAK2
Immunomodulation

Viral Replication

Ruxolitinib (free base)

AG-CR1-3624

941678-49-5

JAK1/JAK2
Immunomodulation

Viral Replication

Saquinavir . mesylate

AG-CR1-3727

149845-06-7

Main Protease Mpro

Viral Replication

Shikonin

AG-CN2-0487

517-89-5

Main Protease (Mpro)/3C-like Protease

Viral Transcription/Replication

Tofacitinib

AG-CR1-3625

477600-75-2

JAK1/JAK3
Immunomodulation

Viral Replication

Tofacitinib citrate

AG-CR1-3732

540737-29-9

JAK1/JAK3
Immunomodulation

Viral Replication

Tofacitinib citrate

CDX-T0461

540737-29-9

JAK1/JAK3
Immunomodulation

Viral Replication

Umifenovir . HCl [Arbidol]

AG-CR1-3718

131707-23-8

Viral entry
Fusion into host cells

Viral Replication

NOT FOR HUMAN USE


Cytokine Storm and Severity of COVID-19

The most critically ill COVID-19 patients are known to undergo a cytokine storm leading to poor prognosis and need of urgent anti-inflammatory treatment/hospitalization. There are many variations on this phenomenon and they go by many names: systemic inflammatory response syndrome, macrophage activation syndrome or cytokine release syndrome (CRS).

A cytokine storm is an overproduction of immune cells and their activating compounds, the cytokines.  When SARS-CoV-2 enters the lungs, it triggers an immune response, attracting immune cells to the region to attack the virus, resulting in localized inflammation. But in some patients, excessive or uncontrolled levels of cytokines are released which then activate more immune cells, resulting in hyperinflammation. The resulting lung inflammation and fluid buildup can lead to respiratory distress and can be contaminated by a secondary bacterial pneumonia. This increases the risk of mortality in patients. Cytokine storms might explain why some people have a severe reaction to coronaviruses while others only experience mild symptoms. They could also be the reason why younger people are less affected, as their immune systems are less developed and so produce lower levels of inflammation-driving cytokines. Cytokine storms are a common complication not only of COVID-19 and flu but of other respiratory diseases caused by coronaviruses such as SARS and MERS. They are also associated with non-infectious diseases such as multiple sclerosis and pancreatitis.

Therefore the diagnostic detection and treatment of cytokine storms has become an important part of rescuing severe patients. Targets like IL-1, IL-6, IL-7, IL-10, IL-18, IL-33, IFN-γ, TNF-α or many others might play an important role in cytokine release syndrome (CRS). Detection of their levels and blockage of their signaling pathways with immunomodulatory agents (biologicals, small molecules) is expected to become a new method for the treatment of severe patients.

AdipoGen Life Sciences offers a broad range of Cytokine Immunoassays as well as recombinant cytokines and blocking antibodies, which are already being successfully used to research the various cytokine storm factors involved and to characterize the immune response. 

 

LITERATURE REFERENCES:

  1. COVID-19: consider cytokine storm syndromes and immunosuppression: P. Mehta, et al. ; The Lancet 395, p1033 (2020)
  2. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality: C. Zhang, et al. ; Int. J. Antimicrob. Agents (Epub ahead of print) (2020)

 


Selected Biologicals for Cytokine Storm Research

 

Target

Product Name

PID

Interleukin-6

Cymax IL-6 (human) ELISA Kit

YIF-LF-EK0260

 

IL-6 (human):Fc (human) (rec.)

CHI-HF-21006

Interleukin-1 Family / Inflammasome

IL-1β (human) (rec.) (untagged)

AG-40B-0023

 

Cymax IL-1β (human) ELISA Kit

YIF-LF-EK0276

 

anti-NLRP3/NALP3, mAb (Cryo-2)

AG-20B-0014

 

anti-Caspase-1 (p20) (human), mAb (Bally-1)

AG-20B-0048

Interleukin-33

IL-33 (human) (rec.) (untagged)

AG-40B-0038

 

IL-33 (oxidation resistant) (human) (rec.) (His)

AG-40B-0167

 

IL-33 (oxidation resistant) (human) (rec.) (untagged)

AG-40B-0160

 

anti-IL-33 (human), mAb (IL33305B)

AG-20A-0041

 

anti-IL-33 (mouse), mAb (rec.) (blocking) (Bondy-1-1) (PF)

AG-27B-0013PF

 

IL-33 (human) ELISA Kit

AG-45A-0033YEK

GM-CSF

GM-CSF (human) (rec.) (His)

CHI-HR-200CSF

Interleukin-2

IL-2 (human) (rec.) (untagged)

CHI-HR-20602

 

IL-2 Superkine (Fc)

AG-40B-0111

 

IL-2 Superkine (untagged)

AG-40B-0187

TNF-α

TNF-α, Soluble (human) (rec.)

AG-40B-0006

 

TNF-α (human) (multimeric) (rec.)

AG-40B-0019

 

anti-TNF-α (human), mAb (J1D9)

ANC-398-020

 

anti-TNF-α (mouse), mAb (blocking) (V1q) (PF)

AG-20B-0081PF

Interleukin-10

IL-10 (human) (rec.) (untagged)

CHI-HR-20610

 

IL-10 (human):Fc (human) (rec.) (non-lytic)

CHI-HF-22010

For More Products please search our Website www.adipogen.com

   

 


More Information


 

Product Flyer


Reagents for SARS-CoV-2/COVID-19 Research

• Blocking human ACE2 antibody
• Soluble recombinant human ACE2 protein, produced in mammalian cells (HEK 293)
• Recombinant SARS-CoV-2 RBD Domain
• ACE2 (human) ELISA Kit
• Anti-SARS-CoV-2 Serological IgG Assay
• Anti-SARS-CoV-2 Screening Assay
• Small Molecule SARS-CoV-2 Infection Inhibitors/Modulators


 

 



Coming Soon


 

interligne
interligne
SARS-CoV-2 Nucleocapsid Protein (rec.) (His) SARS-CoV-2 Nucleocapsid Protein (rec.) (His) 100 µg Ref. CHI-B233501-C100 Marque ADIPOGEN LIFE SCIENCES 390.00 351.00 H.T.
 
ACE2 (human):Fc (human) (rec.) ACE2 (human):Fc (human) (rec.) 100 µg Ref. CHI-B232006-C100 Marque ADIPOGEN LIFE SCIENCES 520.00 468.00 H.T.
 
interligne
SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) 100 µg Ref. CHI-B232004-C100 Marque ADIPOGEN LIFE SCIENCES 480.00 432.00 H.T.
 
interligne
Elbasvir Elbasvir 25 mg Ref. AG-CR1-3729-M025 Marque ADIPOGEN LIFE SCIENCES 390.00 351.00 H.T.
 
Elbasvir Elbasvir 5 mg Ref. AG-CR1-3729-M005 Marque ADIPOGEN LIFE SCIENCES 130.00 117.00 H.T.
 
interligne
Elbasvir Elbasvir 1 mg Ref. AG-CR1-3729-M001 Marque ADIPOGEN LIFE SCIENCES 45.00 40.50 H.T.
 
Rosuvastatin . calcium salt Rosuvastatin . calcium salt 250 mg Ref. AG-CR1-3728-M250 Marque ADIPOGEN LIFE SCIENCES 180.00 162.00 H.T.
 
interligne
Rosuvastatin . calcium salt Rosuvastatin . calcium salt 50 mg Ref. AG-CR1-3728-M050 Marque ADIPOGEN LIFE SCIENCES 50.00 45.00 H.T.
 
Rosuvastatin . calcium salt Rosuvastatin . calcium salt 10 mg Ref. AG-CR1-3728-M010 Marque ADIPOGEN LIFE SCIENCES 25.00 22.50 H.T.
 
interligne
Saquinavir . mesylate Saquinavir . mesylate 50 mg Ref. AG-CR1-3727-M050 Marque ADIPOGEN LIFE SCIENCES 150.00 135.00 H.T.
 
Saquinavir . mesylate Saquinavir . mesylate 10 mg Ref. AG-CR1-3727-M010 Marque ADIPOGEN LIFE SCIENCES 50.00 45.00 H.T.
 
interligne
Nelfinavir . mesylate Nelfinavir . mesylate 50 mg Ref. AG-CR1-3726-M050 Marque ADIPOGEN LIFE SCIENCES 200.00 180.00 H.T.
 
Nelfinavir . mesylate Nelfinavir . mesylate 10 mg Ref. AG-CR1-3726-M010 Marque ADIPOGEN LIFE SCIENCES 50.00 45.00 H.T.
 
interligne
Imatinib . mesylate Imatinib . mesylate 250 mg Ref. AG-CR1-3725-M250 Marque ADIPOGEN LIFE SCIENCES 180.00 162.00 H.T.
 
Imatinib . mesylate Imatinib . mesylate 100 mg Ref. AG-CR1-3725-M100 Marque ADIPOGEN LIFE SCIENCES 60.00 54.00 H.T.
 
interligne
Imatinib . mesylate Imatinib . mesylate 25 mg Ref. AG-CR1-3725-M025 Marque ADIPOGEN LIFE SCIENCES 30.00 27.00 H.T.
 
Darunavir . ethanolate Darunavir . ethanolate 250 mg Ref. AG-CR1-3724-M250 Marque ADIPOGEN LIFE SCIENCES 450.00 405.00 H.T.
 
interligne
Darunavir . ethanolate Darunavir . ethanolate 50 mg Ref. AG-CR1-3724-M050 Marque ADIPOGEN LIFE SCIENCES 180.00 162.00 H.T.
 
Darunavir . ethanolate Darunavir . ethanolate 10 mg Ref. AG-CR1-3724-M010 Marque ADIPOGEN LIFE SCIENCES 60.00 54.00 H.T.
 
interligne
Nitazoxanide Nitazoxanide 250 mg Ref. AG-CR1-3723-M250 Marque ADIPOGEN LIFE SCIENCES 480.00 432.00 H.T.
 
Nitazoxanide Nitazoxanide 50 mg Ref. AG-CR1-3723-M050 Marque ADIPOGEN LIFE SCIENCES 160.00 144.00 H.T.
 
interligne
Nitazoxanide Nitazoxanide 10 mg Ref. AG-CR1-3723-M010 Marque ADIPOGEN LIFE SCIENCES 40.00 36.00 H.T.
 
GS-441524 (Remdesivir Metabolite) GS-441524 (Remdesivir Metabolite) 50 mg Ref. AG-CR1-3722-M050 Marque ADIPOGEN LIFE SCIENCES 210.00 189.00 H.T.
 
interligne
GS-441524 (Remdesivir Metabolite) GS-441524 (Remdesivir Metabolite) 10 mg Ref. AG-CR1-3722-M010 Marque ADIPOGEN LIFE SCIENCES 80.00 72.00 H.T.
 
GS-441524 (Remdesivir Metabolite) GS-441524 (Remdesivir Metabolite) 5 mg Ref. AG-CR1-3722-M005 Marque ADIPOGEN LIFE SCIENCES 50.00 45.00 H.T.
 
interligne
Chloroquine . diphosphate Chloroquine . diphosphate 25 g Ref. AG-CR1-3721-G025 Marque ADIPOGEN LIFE SCIENCES 80.00 72.00 H.T.
 
Chloroquine . diphosphate Chloroquine . diphosphate 5 g Ref. AG-CR1-3721-G005 Marque ADIPOGEN LIFE SCIENCES 50.00 45.00 H.T.
 
interligne
Chloroquine . diphosphate Chloroquine . diphosphate 1 g Ref. AG-CR1-3721-G001 Marque ADIPOGEN LIFE SCIENCES 20.00 18.00 H.T.
 
Hydroxychloroquine sulfate Hydroxychloroquine sulfate 1 g Ref. AG-CR1-3720-G001 Marque ADIPOGEN LIFE SCIENCES 180.00 162.00 H.T.
 
interligne
Hydroxychloroquine . sulfate Hydroxychloroquine . sulfate 250 mg Ref. AG-CR1-3720-M250 Marque ADIPOGEN LIFE SCIENCES 120.00 108.00 H.T.
 
Hydroxychloroquine . sulfate Hydroxychloroquine . sulfate 50 mg Ref. AG-CR1-3720-M050 Marque ADIPOGEN LIFE SCIENCES 35.00 31.50 H.T.
 
interligne
Ribavirin Ribavirin 1 g Ref. AG-CR1-3719-G001 Marque ADIPOGEN LIFE SCIENCES 90.00 81.00 H.T.
 
Ribavirin Ribavirin 250 mg Ref. AG-CR1-3719-M250 Marque ADIPOGEN LIFE SCIENCES 50.00 45.00 H.T.
 
interligne
Ribavirin Ribavirin 50 mg Ref. AG-CR1-3719-M050 Marque ADIPOGEN LIFE SCIENCES 20.00 18.00 H.T.
 
Umifenovir . HCl [Arbidol] Umifenovir . HCl [Arbidol] 250 mg Ref. AG-CR1-3718-M250 Marque ADIPOGEN LIFE SCIENCES 450.00 405.00 H.T.
 
interligne
Umifenovir . HCl [Arbidol] Umifenovir . HCl [Arbidol] 50 mg Ref. AG-CR1-3718-M050 Marque ADIPOGEN LIFE SCIENCES 150.00 135.00 H.T.
 
Umifenovir . HCl [Arbidol] Umifenovir . HCl [Arbidol] 10 mg Ref. AG-CR1-3718-M010 Marque ADIPOGEN LIFE SCIENCES 50.00 45.00 H.T.
 
interligne
Favipiravir Favipiravir 100 mg Ref. AG-CR1-3717-M100 Marque ADIPOGEN LIFE SCIENCES 140.00 126.00 H.T.
 
Favipiravir Favipiravir 25 mg Ref. AG-CR1-3717-M025 Marque ADIPOGEN LIFE SCIENCES 70.00 63.00 H.T.
 
interligne
Favipiravir Favipiravir 5 mg Ref. AG-CR1-3717-M005 Marque ADIPOGEN LIFE SCIENCES 40.00 36.00 H.T.
 
Camostat . mesylate Camostat . mesylate 250 mg Ref. AG-CR1-3716-M250 Marque ADIPOGEN LIFE SCIENCES 450.00 405.00 H.T.
 
interligne
Camostat . mesylate Camostat . mesylate 50 mg Ref. AG-CR1-3716-M050 Marque ADIPOGEN LIFE SCIENCES 180.00 162.00 H.T.
 
Camostat . mesylate Camostat . mesylate 10 mg Ref. AG-CR1-3716-M010 Marque ADIPOGEN LIFE SCIENCES 50.00 45.00 H.T.
 
interligne
Lopinavir Lopinavir 250 mg Ref. AG-CR1-3715-M250 Marque ADIPOGEN LIFE SCIENCES 190.00 171.00 H.T.
 
Lopinavir Lopinavir 100 mg Ref. AG-CR1-3715-M100 Marque ADIPOGEN LIFE SCIENCES 105.00 94.50 H.T.
 
interligne
Lopinavir Lopinavir 25 mg Ref. AG-CR1-3715-M025 Marque ADIPOGEN LIFE SCIENCES 35.00 31.50 H.T.
 
Oseltamivir . phosphate Oseltamivir . phosphate 250 mg Ref. AG-CR1-3714-M250 Marque ADIPOGEN LIFE SCIENCES 110.00 99.00 H.T.
 
interligne
Oseltamivir . phosphate Oseltamivir . phosphate 100 mg Ref. AG-CR1-3714-M100 Marque ADIPOGEN LIFE SCIENCES 50.00 45.00 H.T.
 
Oseltamivir . phosphate Oseltamivir . phosphate 25 mg Ref. AG-CR1-3714-M025 Marque ADIPOGEN LIFE SCIENCES 30.00 27.00 H.T.
 
interligne